Nuclear Receptor-Targeting Compounds for Selective Topoisomerase Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topoisomerase inhibitors, such as camptothecin, suffer from low solubility and adverse effects, limiting their therapeutic efficacy and specificity in cancer treatment.
Innovation Solution
Development of compounds comprising a nuclear payload and a nuclear receptor-targeting epitope, allowing targeted delivery and accumulation in tumor cells, enhancing tumor cell death while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topoisomerase inhibitors like camptothecin are used to treat cancer, then anticancer activity is improved, but solubility deteriorates and adverse effects increase
Solution Approach 1:
The compound is divided into two functional segments: a nuclear payload (topoisomerase inhibitor) and a nuclear receptor-targeting epitope. This segmentation allows each component to perform its specific function independently, with the epitope segment improving solubility and targeting while the payload segment maintains anticancer activity.
Solution Approach 2:
The invention creates a composite compound by covalently attaching the nuclear receptor-targeting epitope to the topoisomerase inhibitor. This composite structure combines the pharmacological activity of the inhibitor with the solubility-enhancing and targeting properties of the epitope, resolving the contradiction between efficacy and solubility.
2Reliability
If topoisomerase inhibitors are used to treat cancer, then anticancer activity is improved, but adverse effects worsen
Solution Approach 1:
The nuclear receptor-targeting epitope provides local quality by conferring cell-type selectivity to the compound. The epitope enables preferential accumulation in nuclear receptor-positive tumor cells, concentrating the therapeutic effect where needed while reducing exposure and adverse effects in normal tissues.
Solution Approach 2:
The nuclear receptor-targeting epitope acts as an intermediary that mediates selective delivery of the topoisomerase inhibitor to tumor cells. This intermediary function allows the compound to navigate biological barriers and achieve selective accumulation, reducing off-target adverse effects while maintaining anticancer activity.
3Reliability
If conventional topoisomerase inhibitors are administered, then anticancer activity is achieved, but cell-type selectivity deteriorates
Solution Approach 1:
The nuclear receptor-targeting epitope imparts local quality by providing cell-type-specific recognition. Different epitopes can be selected to target different nuclear receptors, allowing the same topoisomerase inhibitor payload to be selectively delivered to various tumor cell types expressing specific nuclear receptors.
Solution Approach 2:
The modular design provides universality by allowing the same topoisomerase inhibitor payload to be combined with different nuclear receptor-targeting epitopes. This multi-functionality enables a single platform to target multiple tumor types based on their nuclear receptor expression profiles, improving adaptability while maintaining anticancer activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve superior efficacy in treating various cancers by accumulating in the nucleus of nuclear receptor-positive cells, reducing side effects and improving therapeutic index.
Implementation Method 1
The compounds described herein are designed to bind nuclear receptors within the cell and allow the compound, with its nuclear payload, to accumulate in the nucleus
Data Source
AI summary
Provided herein are compounds comprising a nuclear payload, such as a topoisomerase inhibitor, topoisomerase poison, or analog thereof, and a nuclear receptor-targeting epitope.